Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,659
archived clinical trials in
Metabolic

The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated:  12/31/1969
IONIS Investigative Site
mi
from
Oklahoma City, OK
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated: 12/31/1969
IONIS Investigative Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated:  12/31/1969
IONIS Investigative Site
mi
from
Portland, OR
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated: 12/31/1969
IONIS Investigative Site
mi
from
Portland, OR
Click here to add this to my saved trials
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated:  12/31/1969
IONIS Investigative Site
mi
from
Providence, RI
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated: 12/31/1969
IONIS Investigative Site
mi
from
Providence, RI
Click here to add this to my saved trials
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated:  12/31/1969
IONIS Investigative Site
mi
from
Houston, TX
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated: 12/31/1969
IONIS Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated:  12/31/1969
IONIS Investigative Site
mi
from
Salt Lake City, UT
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated: 12/31/1969
IONIS Investigative Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated:  12/31/1969
IONIS Investigative Site
mi
from
Norfolk, VA
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated: 12/31/1969
IONIS Investigative Site
mi
from
Norfolk, VA
Click here to add this to my saved trials
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated:  12/31/1969
IONIS Investigative Site
mi
from
Seattle, WA
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated: 12/31/1969
IONIS Investigative Site
mi
from
Seattle, WA
Click here to add this to my saved trials
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated:  12/31/1969
IONIS Investigative Site
mi
from
Vancouver,
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated: 12/31/1969
IONIS Investigative Site
mi
from
Vancouver,
Click here to add this to my saved trials
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated:  12/31/1969
IONIS Investigative Site
mi
from
North Massapequa, NY
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Status: Enrolling
Updated: 12/31/1969
IONIS Investigative Site
mi
from
North Massapequa, NY
Click here to add this to my saved trials
Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)
A Phase 2b, Open-Label, Long-Term Extension Study to Evaluate the Safety and Pharmacodynamics of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)
Status: Enrolling
Updated:  12/31/1969
University of California San Francisco Hospital
mi
from
San Francisco, CA
Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)
A Phase 2b, Open-Label, Long-Term Extension Study to Evaluate the Safety and Pharmacodynamics of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)
Status: Enrolling
Updated: 12/31/1969
University of California San Francisco Hospital
mi
from
San Francisco, CA
Click here to add this to my saved trials
Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)
A Phase 2b, Open-Label, Long-Term Extension Study to Evaluate the Safety and Pharmacodynamics of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)
Status: Enrolling
Updated:  12/31/1969
Yale University School of Medicine
mi
from
New Haven, CT
Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)
A Phase 2b, Open-Label, Long-Term Extension Study to Evaluate the Safety and Pharmacodynamics of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)
Status: Enrolling
Updated: 12/31/1969
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)
A Phase 2b, Open-Label, Long-Term Extension Study to Evaluate the Safety and Pharmacodynamics of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)
Status: Enrolling
Updated:  12/31/1969
Indiana University Hospital
mi
from
Indianapolis, IN
Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)
A Phase 2b, Open-Label, Long-Term Extension Study to Evaluate the Safety and Pharmacodynamics of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)
Status: Enrolling
Updated: 12/31/1969
Indiana University Hospital
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)
A Phase 2b, Open-Label, Long-Term Extension Study to Evaluate the Safety and Pharmacodynamics of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)
Status: Enrolling
Updated:  12/31/1969
Duke University
mi
from
Durham, NC
Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)
A Phase 2b, Open-Label, Long-Term Extension Study to Evaluate the Safety and Pharmacodynamics of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)
Status: Enrolling
Updated: 12/31/1969
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)
A Phase 2b, Open-Label, Long-Term Extension Study to Evaluate the Safety and Pharmacodynamics of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)
Status: Enrolling
Updated:  12/31/1969
Houston Methodist Reasearch Institute
mi
from
Houston, TX
Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)
A Phase 2b, Open-Label, Long-Term Extension Study to Evaluate the Safety and Pharmacodynamics of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)
Status: Enrolling
Updated: 12/31/1969
Houston Methodist Reasearch Institute
mi
from
Houston, TX
Click here to add this to my saved trials
Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)
A Phase I/II Open Label Study in MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Minneapolis, MN
Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)
A Phase I/II Open Label Study in MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)
A Phase I/II Open Label Study in MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Pittsburgh, PA
Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)
A Phase I/II Open Label Study in MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)
A Phase I/II Open Label Study in MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously
Status: Enrolling
Updated:  12/31/1969
Research Site
mi
from
Barcelona,
Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)
A Phase I/II Open Label Study in MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously
Status: Enrolling
Updated: 12/31/1969
Research Site
mi
from
Barcelona,
Click here to add this to my saved trials
Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Iduronate 2-Sulfatase (IDS) Fusion Protein, AGT-182 in Adult Patients With Mucopolysaccharidosis II (MPS II, Hunter Syndrome)
Status: Enrolling
Updated:  12/31/1969
Children's Hospital Oakland
mi
from
Oakland, CA
Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Iduronate 2-Sulfatase (IDS) Fusion Protein, AGT-182 in Adult Patients With Mucopolysaccharidosis II (MPS II, Hunter Syndrome)
Status: Enrolling
Updated: 12/31/1969
Children's Hospital Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Iduronate 2-Sulfatase (IDS) Fusion Protein, AGT-182 in Adult Patients With Mucopolysaccharidosis II (MPS II, Hunter Syndrome)
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Orange County
mi
from
Orange, CA
Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Iduronate 2-Sulfatase (IDS) Fusion Protein, AGT-182 in Adult Patients With Mucopolysaccharidosis II (MPS II, Hunter Syndrome)
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Orange County
mi
from
Orange, CA
Click here to add this to my saved trials
Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Iduronate 2-Sulfatase (IDS) Fusion Protein, AGT-182 in Adult Patients With Mucopolysaccharidosis II (MPS II, Hunter Syndrome)
Status: Enrolling
Updated:  12/31/1969
Emory University
mi
from
Decatur, GA
Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Iduronate 2-Sulfatase (IDS) Fusion Protein, AGT-182 in Adult Patients With Mucopolysaccharidosis II (MPS II, Hunter Syndrome)
Status: Enrolling
Updated: 12/31/1969
Emory University
mi
from
Decatur, GA
Click here to add this to my saved trials
Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Iduronate 2-Sulfatase (IDS) Fusion Protein, AGT-182 in Adult Patients With Mucopolysaccharidosis II (MPS II, Hunter Syndrome)
Status: Enrolling
Updated:  12/31/1969
ZKJM MC University of Mainz
mi
from
Mainz,
Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Iduronate 2-Sulfatase (IDS) Fusion Protein, AGT-182 in Adult Patients With Mucopolysaccharidosis II (MPS II, Hunter Syndrome)
Status: Enrolling
Updated: 12/31/1969
ZKJM MC University of Mainz
mi
from
Mainz,
Click here to add this to my saved trials
An Open-Label Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Treatment in Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7) Patients Less Than 5 Years of Age
An Open-label Study of UX003 rhGUS Enzyme Replacement Therapy in MPS 7 Patients Less Than 5 Years Old
Status: Enrolling
Updated:  12/31/1969
New York University Langone Medical Center
mi
from
New York, NY
An Open-Label Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Treatment in Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7) Patients Less Than 5 Years of Age
An Open-label Study of UX003 rhGUS Enzyme Replacement Therapy in MPS 7 Patients Less Than 5 Years Old
Status: Enrolling
Updated: 12/31/1969
New York University Langone Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
An Open-Label Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Treatment in Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7) Patients Less Than 5 Years of Age
An Open-label Study of UX003 rhGUS Enzyme Replacement Therapy in MPS 7 Patients Less Than 5 Years Old
Status: Enrolling
Updated:  12/31/1969
University Of Utah Hospital
mi
from
Salt Lake City, UT
An Open-Label Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Treatment in Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7) Patients Less Than 5 Years of Age
An Open-label Study of UX003 rhGUS Enzyme Replacement Therapy in MPS 7 Patients Less Than 5 Years Old
Status: Enrolling
Updated: 12/31/1969
University Of Utah Hospital
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
An Open-Label Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Treatment in Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7) Patients Less Than 5 Years of Age
An Open-label Study of UX003 rhGUS Enzyme Replacement Therapy in MPS 7 Patients Less Than 5 Years Old
Status: Enrolling
Updated:  12/31/1969
Children's National Health System
mi
from
Washington,
An Open-Label Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Treatment in Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7) Patients Less Than 5 Years of Age
An Open-label Study of UX003 rhGUS Enzyme Replacement Therapy in MPS 7 Patients Less Than 5 Years Old
Status: Enrolling
Updated: 12/31/1969
Children's National Health System
mi
from
Washington,
Click here to add this to my saved trials
An Open-Label Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Treatment in Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7) Patients Less Than 5 Years of Age
An Open-label Study of UX003 rhGUS Enzyme Replacement Therapy in MPS 7 Patients Less Than 5 Years Old
Status: Enrolling
Updated:  12/31/1969
Centro Hospitalar do Porto
mi
from
Porto,
An Open-Label Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Treatment in Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7) Patients Less Than 5 Years of Age
An Open-label Study of UX003 rhGUS Enzyme Replacement Therapy in MPS 7 Patients Less Than 5 Years Old
Status: Enrolling
Updated: 12/31/1969
Centro Hospitalar do Porto
mi
from
Porto,
Click here to add this to my saved trials
A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7
A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7
Status: Enrolling
Updated:  12/31/1969
Children's Hospital Oakland
mi
from
Oakland, CA
A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7
A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7
Status: Enrolling
Updated: 12/31/1969
Children's Hospital Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7
A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Orange County
mi
from
Orange, CA
A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7
A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Orange County
mi
from
Orange, CA
Click here to add this to my saved trials
A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7
A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7
Status: Enrolling
Updated:  12/31/1969
Univ of Minnesota
mi
from
Minneapolis, MN
A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7
A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7
Status: Enrolling
Updated: 12/31/1969
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7
A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7
Status: Enrolling
Updated:  12/31/1969
Texas Children's Hospital
mi
from
Houston, TX
A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7
A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7
Status: Enrolling
Updated: 12/31/1969
Texas Children's Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7
A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7
Status: Enrolling
Updated:  12/31/1969
Hospital Infantil Candido Fontoura Sao Paulo
mi
from
Sao Paulo,
A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7
A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7
Status: Enrolling
Updated: 12/31/1969
Hospital Infantil Candido Fontoura Sao Paulo
mi
from
Sao Paulo,
Click here to add this to my saved trials
Non-steroidal Anti-inflammatory Affect on Kidneys in Endurance Distances
Non-steroidal Anti-inflammatory Affect on Kidneys in Endurance Distances
Status: Enrolling
Updated:  12/31/1969
Stanford University
mi
from
Stanford, CA
Non-steroidal Anti-inflammatory Affect on Kidneys in Endurance Distances
Non-steroidal Anti-inflammatory Affect on Kidneys in Endurance Distances
Status: Enrolling
Updated: 12/31/1969
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
Tolvaptan for Patients With Acute Neurological Injuries
Use of Tolvaptan to Treat SIADH-induced Hyponatremia in Selected Patients With Acute Neurological Injuries
Status: Enrolling
Updated:  12/31/1969
Mercy Hospital
mi
from
Pittsburgh, PA
Tolvaptan for Patients With Acute Neurological Injuries
Use of Tolvaptan to Treat SIADH-induced Hyponatremia in Selected Patients With Acute Neurological Injuries
Status: Enrolling
Updated: 12/31/1969
Mercy Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Tolvaptan for Patients With Acute Neurological Injuries
Use of Tolvaptan to Treat SIADH-induced Hyponatremia in Selected Patients With Acute Neurological Injuries
Status: Enrolling
Updated:  12/31/1969
UPMC Presbyterian
mi
from
Pittsburgh, PA
Tolvaptan for Patients With Acute Neurological Injuries
Use of Tolvaptan to Treat SIADH-induced Hyponatremia in Selected Patients With Acute Neurological Injuries
Status: Enrolling
Updated: 12/31/1969
UPMC Presbyterian
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Oxidative Stress-Related Biomarkers in Gaucher Disease: A Preliminary Study
Oxidative Stress-Related Biomarkers in Gaucher Disease: A Preliminary Study
Status: Enrolling
Updated:  12/31/1969
Univ of Minnesota
mi
from
Minneapolis, MN
Oxidative Stress-Related Biomarkers in Gaucher Disease: A Preliminary Study
Oxidative Stress-Related Biomarkers in Gaucher Disease: A Preliminary Study
Status: Enrolling
Updated: 12/31/1969
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
SRT in Comparison to ERT on Immune Aspects and Bone Involvement in Gaucher Disease
Effect of Two Different Therapeutic Interventions: SRT in Comparison to ERT on Immune Aspects and Bone Involvement in Gaucher Disease
Status: Enrolling
Updated:  12/31/1969
O&O Alpan
mi
from
Fairfax, VA
SRT in Comparison to ERT on Immune Aspects and Bone Involvement in Gaucher Disease
Effect of Two Different Therapeutic Interventions: SRT in Comparison to ERT on Immune Aspects and Bone Involvement in Gaucher Disease
Status: Enrolling
Updated: 12/31/1969
O&O Alpan
mi
from
Fairfax, VA
Click here to add this to my saved trials
Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
Status: Enrolling
Updated:  12/31/1969
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
Status: Enrolling
Updated: 12/31/1969
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
Status: Enrolling
Updated:  12/31/1969
University of California, San Francisco Medical Center
mi
from
San Francisco, CA
Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
Status: Enrolling
Updated: 12/31/1969
University of California, San Francisco Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
Status: Enrolling
Updated:  12/31/1969
Yale University School of Medicine
mi
from
New Haven, CT
Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
Status: Enrolling
Updated: 12/31/1969
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
Status: Enrolling
Updated:  12/31/1969
Indiana University Department of Medicine
mi
from
Indianapolis, IN
Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
Status: Enrolling
Updated: 12/31/1969
Indiana University Department of Medicine
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
Status: Enrolling
Updated:  12/31/1969
The Ohio State University, Wexner Medical Center
mi
from
Columbus, OH
Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
Status: Enrolling
Updated: 12/31/1969
The Ohio State University, Wexner Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
Status: Enrolling
Updated:  12/31/1969
Houston Methodist Hospital
mi
from
Houston, TX
Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
Status: Enrolling
Updated: 12/31/1969
Houston Methodist Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
Status: Enrolling
Updated:  12/31/1969
CHU de Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction
mi
from
Le Kremlin-Bicêtre,
Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
Status: Enrolling
Updated: 12/31/1969
CHU de Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction
mi
from
Le Kremlin-Bicêtre,
Click here to add this to my saved trials
Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)
An Open-Label, Single-Arm, Phase 3 Study to Evaluate the Effects of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)
Status: Enrolling
Updated:  12/31/1969
UCSF Medical Center at Mission
mi
from
San Francisco, CA
Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)
An Open-Label, Single-Arm, Phase 3 Study to Evaluate the Effects of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)
Status: Enrolling
Updated: 12/31/1969
UCSF Medical Center at Mission
mi
from
San Francisco, CA
Click here to add this to my saved trials
Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)
An Open-Label, Single-Arm, Phase 3 Study to Evaluate the Effects of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)
Status: Enrolling
Updated:  12/31/1969
Yale University School of Medicine - Yale New-Haven Hospital/Yale Center for Clinical Investigation
mi
from
New Haven, CT
Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)
An Open-Label, Single-Arm, Phase 3 Study to Evaluate the Effects of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)
Status: Enrolling
Updated: 12/31/1969
Yale University School of Medicine - Yale New-Haven Hospital/Yale Center for Clinical Investigation
mi
from
New Haven, CT
Click here to add this to my saved trials
Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)
An Open-Label, Single-Arm, Phase 3 Study to Evaluate the Effects of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)
Status: Enrolling
Updated:  12/31/1969
Indiana University Department of Medicine University Hospital
mi
from
Indianapolis, IN
Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)
An Open-Label, Single-Arm, Phase 3 Study to Evaluate the Effects of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)
Status: Enrolling
Updated: 12/31/1969
Indiana University Department of Medicine University Hospital
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)
An Open-Label, Single-Arm, Phase 3 Study to Evaluate the Effects of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)
An Open-Label, Single-Arm, Phase 3 Study to Evaluate the Effects of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)
An Open-Label, Single-Arm, Phase 3 Study to Evaluate the Effects of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)
Status: Enrolling
Updated:  12/31/1969
Houston Methodist Hospital
mi
from
Houston, TX
Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)
An Open-Label, Single-Arm, Phase 3 Study to Evaluate the Effects of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)
Status: Enrolling
Updated: 12/31/1969
Houston Methodist Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)
An Open-Label, Single-Arm, Phase 3 Study to Evaluate the Effects of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Eastern Ontario
mi
from
Ottawa,
Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)
An Open-Label, Single-Arm, Phase 3 Study to Evaluate the Effects of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Eastern Ontario
mi
from
Ottawa,
Click here to add this to my saved trials